Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study

Journal of Hepatology

Volumn 63, Issue 4, 2015, Pages 896-904

  Cheng, Ann Lii ^a   Kang, Yoon Koo ^b   He, Aiwu Ruth ^c   Lim, Ho Yeong ^d   Ryoo, Baek Yeol ^b   Hung, Chao Hung ^e   Sheen, I Shyan ^f   Izumi, Namiki ^g   Austin, Tashara ^h   Wang, Qiang ⁱ   Greenberg, Jonathan ⁱ   Shiratori, Shinichi ⁱ   Beckman, Robert A ^c   Kudo, Masatoshi ^j  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b University of Ulsan College of Medicine   (South Korea)

^c GEORGETOWN UNIVERSITY   (United States)

^d Sungkyunkwan University   (South Korea)

^e Chang Gung Medical Foundation   (Taiwan)

^f Medical Center   (Taiwan)

^g MUSASHINO RED CROSS HOSPITAL   (Japan)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ DAIICHI SANKYO INC   (United States)

^j KINDAI UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Advanced hepatocellular carcinoma; Combination therapy; CS 1008; Monoclonal antibody; Sorafenib; Tigatuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; SORAFENIB; TIGATUZUMAB PLUS SORAFENIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE; TIGATUZUMAB; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; HAND FOOT SYNDROME; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; LOADING DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER ABDOMINAL PAIN; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84941941332     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.06.001     Document Type: Article

References (29)

1. G.L. Davis, J. Dempster, J.D. Meler, D.W. Orr, M.W. Walberg, B. Brown, and et al. Hepatocellular carcinoma: management of an increasingly common problem Proc (Bayl Univ Med Cent) 21 2008 266 280
2. J.H. Kao, and D.S. Chen Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia Liver Int 25 2005 696 703
3. A. Forner, J.M. Llovet, and J. Bruix Hepatocellular carcinoma Lancet 379 2012 1245 1255
4. S.F. Altekruse, K.A. McGlynn, and M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 2009 1485 1491
5. R. Dhanasekaran, A. Limaye, and R. Cabrera Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics Hepat Med Evid Res 4 2012 19 37
6. I. Herr, P. Schemmer, and M.W. Buchler On the TRAIL to therapeutic intervention in liver disease Hepatology 46 2007 266 274
7. S.R. Nerenstone, D.C. Ihde, and M.A. Friedman Clinical trials in primary hepatocellular carcinoma: current status and future directions Cancer Treat Rev 15 1988 1 31
8. S. Okada, N. Okazaki, H. Nose, M. Yoshimori, and K. Aoki Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy Hepatology 16 1992 112 117
9. R. Lencioni Loco-regional treatment of hepatocellular carcinoma Hepatology 52 2010 762 773
10. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of Sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
11. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, J.S. Kim, and et al. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
12. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, and et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
13. A. Yada, M. Yazawa, S. Ishida, H. Yoshida, K. Ichikawa, S. Kurakata, and et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes Ann Oncol 19 2008 1060 1067
14. A. Forero-Torres, J. Shah, T. Wood, J. Posey, R. Carlisle, C. Copigneaux, and et al. Phase I trial of weekly Tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) Cancer Biother Radiopharm 25 2010 13 19
15. K.F. Chen, H.L. Chen, C.W. Shiau, C.Y. Liu, P.Y. Chu, W.T. Tai, and et al. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody Br J Pharmacol 168 2013 658 672
16. X.W. Meng, S.H. Lee, H. Dai, D. Loegering, C. Yu, K. Flatten, and et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for Sorafenib (Bay 43-9006)-induced TRAIL sensitization J Biol Chem 282 2007 29831 29846
17. M.S. Ricci, S.H. Kim, K. Ogi, J.P. Plastaras, J. Ling, W. Wang, and et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or Sorafenib sensitizes resistant human cancer cells to TRAIL-induced death Cancer Cell 12 2007 66 80
18. R.R. Rosato, J.A. Almenara, S. Coe, and S. Grant The multikinase inhibitor Sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation Cancer Res 67 2007 9490 9500
19. S.H. Kim, M.S. Ricci, and W.S. El-Deiry Mcl-1: a gateway to TRAIL sensitization Cancer Res 68 2008 2062 2064
20. R.A. Beckman, L.M. Weiner, and H.M. Davis Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors Cancer 109 2007 170 179
21. R.A. Beckman, R. von Roemeling, and A.M. Scott Monoclonal Antibody Dose Determination and Biodistribution into Solid Tumors Ther Delivery 2 2011 333 344
22. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
23. Bayer Pharma AG. Nexavar (Sorafenib) Summary of Product Characteristics. http://www medicines org uk/emc/medicine/18520/SPC. Accessed December, 2013.
24. NHS Choices. Alcohol-related liver disease - Symptoms. Available at: http://www.nhs.uk/Conditions/Liver-disease-(alcoholic)/Pages/symptoms.aspx. Accessed May 20, 2014.
25. J. Descotes, and A. Gouraud Clinical immunotoxicity of therapeutic proteins Expert Opin Drug Metab Toxicol 4 2008 1537 1549
26. M. Reck, M. Krzakowski, E. Chmielowska, M. Sebastian, D. Hadler, T. Fox, and et al. A randomized, double-blind, placebo-controlled phase 2 study of Tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer Lung Cancer 82 2013 441 448
27. S.K. Chang, W.W. Hlaing, R.Q. Yu, T.W. Lee, I.S. Ganpathi, and K.K. Madhavan Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection Singapore Med J 53 2012 32 35
28. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, A.X. Zhu, and et al. Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
29. J.M. Llovet, T. Decaens, J.L. Raoul, E. Boucher, M. Kudo, C. Chang, and et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to Sorafenib or for whom Sorafenib failed: results from the randomized phase III BRISK-PS study J Clin Oncol 31 2013 3509 3516